MacroGenics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.About MGNX
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.
CEOEric Risser
CEOEric Risser
Employees341
Employees341
HeadquartersRockville, Maryland
HeadquartersRockville, Maryland
Founded2000
Founded2000
Employees341
Employees341
MGNX Key Statistics
Market cap87.30M
Market cap87.30M
Price-Earnings ratio-1.14
Price-Earnings ratio-1.14
Dividend yield—
Dividend yield—
Average volume1.92M
Average volume1.92M
High today—
High today—
Low today—
Low today—
Open price$1.40
Open price$1.40
Volume0.00
Volume0.00
52 Week high$3.60
52 Week high$3.60
52 Week low$0.9897
52 Week low$0.9897
Stock Snapshot
As of today, MacroGenics(MGNX) shares are valued at $1.35. The company's market cap stands at 87.3M, with a P/E ratio of -1.14.
MacroGenics(MGNX) stock opened on 2025-12-16 at $1.40. The price climbed to — and dipped to —.
MacroGenics(MGNX) shares are trading with a volume of 0, against a daily average of 1.92M.
During the past year, MacroGenics(MGNX) stock moved between $0.99 at its lowest and $3.60 at its peak.
During the past year, MacroGenics(MGNX) stock moved between $0.99 at its lowest and $3.60 at its peak.
Analyst ratings
63%
of 8 ratingsBuy
37.5%
Hold
62.5%
Sell
0%
People also own
Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.